.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J02A_AntimycoticsForSystemicUse.J02AA01_AmphotericinB.AmphotericinB .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J02A_AntimycoticsForSystemicUse.J02AA01_AmphotericinB.AmphotericinB| name: | AmphotericinB |
| ATC code: | J02AA01 | route: | intravenous |
| n-compartments | 2 |
Amphotericin B is a polyene antifungal medication used primarily for the treatment of life-threatening systemic fungal infections. It acts by binding to ergosterol in fungal cell membranes, causing cell death. It is approved and widely used, particularly for severe infections caused by Candida, Aspergillus, and Cryptococcus species.
Pharmacokinetic parameters reported for adult patients (both sexes) treated for systemic fungal infections by intravenous administration of amphotericin B deoxycholate.
Groll, AH, et al., & Brüggemann, RJM (2019). Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 68(Suppl 4) S260–S274. DOI:10.1093/cid/ciz076 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31222253
Würthwein, G, et al., & Walsh, TJ (2005). Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrobial agents and chemotherapy 49(12) 5092–5098. DOI:10.1128/AAC.49.12.5092-5098.2005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16304177
Nath, CE, et al., & Earl, JW (2001). Population pharmacokinetics of amphotericin B in children with malignant diseases. British journal of clinical pharmacology 52(6) 671–680. DOI:10.1046/j.0306-5251.2001.01496.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/11736878